Candel Therapeutics Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
42
- Stock Symbol
-
CADL
- Investments
-
1
- Share Price
-
$5.14
- (As of Friday Closing)
Candel Therapeutics General Information
Description
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Contact Information
Website
www.candeltx.comCorporate Office
- 117 Kendrick Street
- Suite 450
- Needham, MA 02494
- United States
Corporate Office
- 117 Kendrick Street
- Suite 450
- Needham, MA 02494
- United States
Candel Therapeutics Stock Performance
As of 06-Dec-2024, Candel Therapeutics’s stock price is $5.14. Its current market cap is $167M with 32.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.14 | $4.90 | $0.81 - $14.30 | $167M | 32.5M | 372K | -$1.73 |
Candel Therapeutics Financials Summary
As of 30-Sep-2024, Candel Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 219,455 | 22,300 | (2,655) | 136,511 |
| Revenue | 0 | 0 | 125 | 125 |
| EBITDA | (50,043) | (36,425) | (10,304) | (35,839) |
| Net Income | (52,199) | (37,939) | (18,794) | (36,124) |
| Total Assets | 21,517 | 41,201 | 77,691 | 89,205 |
| Total Debt | 16,023 | 22,762 | 22,800 | 560 |
Candel Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Candel Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Candel Therapeutics Comparisons
Industry
Financing
Details
Candel Therapeutics Competitors (9)
One of Candel Therapeutics’s 9 competitors is Oncorus, a Formerly VC-backed company based in Andover, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Oncorus | Formerly VC-backed | Andover, MA | ||||
| Aileron Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| Gritstone bio | Formerly VC-backed | Emeryville, CA | ||||
| ImmVira | Venture Capital-Backed | Shenzhen, China | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD |
Candel Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Candel Therapeutics Patents
Candel Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023255676-A1 | Compositions and methods for viral vectors | Pending | 18-Apr-2022 | ||
| US-20220218801-A1 | Combination gmci and atri cancer treatment | Pending | 30-Sep-2019 | ||
| CA-3156171-A1 | Combination gmci and atri cancer treatment | Pending | 30-Sep-2019 | ||
| EP-4037705-A1 | Combination gmci and atri cancer treatment | Pending | 30-Sep-2019 | ||
| EP-4037705-A4 | Combination gmci and atri cancer treatment | Pending | 30-Sep-2019 | C12N9/1205 |
Candel Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Candel Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Candel Therapeutics Investments (1)
Candel Therapeutics’s most recent deal was a Corporate Asset Purchase with PeriphaGen (Herpes Drug Development Platform and Manufacturing Expertise). The deal was made on 08-Jan-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| PeriphaGen (Herpes Drug Development Platform and Manufacturing Expertise) | 08-Jan-2020 | Corporate Asset Purchase | Buildings and Property |
Candel Therapeutics FAQs
-
When was Candel Therapeutics founded?
Candel Therapeutics was founded in 1999.
-
Where is Candel Therapeutics headquartered?
Candel Therapeutics is headquartered in Needham, MA.
-
What is the size of Candel Therapeutics?
Candel Therapeutics has 42 total employees.
-
What industry is Candel Therapeutics in?
Candel Therapeutics’s primary industry is Drug Discovery.
-
Is Candel Therapeutics a private or public company?
Candel Therapeutics is a Public company.
-
What is Candel Therapeutics’s stock symbol?
The ticker symbol for Candel Therapeutics is CADL.
-
What is the current stock price of Candel Therapeutics?
As of 06-Dec-2024 the stock price of Candel Therapeutics is $5.14.
-
What is the current market cap of Candel Therapeutics?
The current market capitalization of Candel Therapeutics is $167M.
-
Who are Candel Therapeutics’s competitors?
Oncorus, Aileron Therapeutics, Gritstone bio, ImmVira, and NexImmune are some of the 9 competitors of Candel Therapeutics.
-
What is Candel Therapeutics’s annual earnings per share (EPS)?
Candel Therapeutics’s EPS for 12 months was -$1.73.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
